TGen News & Press Releases : Baylor Scott & White Research Institute and TGen poised to create early detection test for pancreatic cancer

Arizona Myeloma Network hosts 8th annual 'Living with Myeloma' Conference

Experts from TGen, Mayo Clinic among participants at free forum March 22 in Scottsdale

GLENDALE, Ariz. - March 5, 2014 - The Arizona Myeloma Network (AZMN) will host its 8th annual "Living with Myeloma" Conference on Saturday, March 22, from 8 a.m.-4:30 p.m. at the Chaparral Suites Ballroom, 5001 N. Scottsdale Road, Scottsdale, Ariz.

The free regional conference is open to all patients, caregivers, family, friends and health care professionals who want to learn more about this rare and often misdiagnosed bone marrow cancer.

Each year, nearly 300 participants attend the dynamic "Living with Myeloma" Conference, which provides cutting-edge information about the latest myeloma research and the newest and most exciting therapies for myeloma cancer patients.

The conference details information about transplant therapy and other new treatment options, including clinical trial opportunities. It also provides a unique opportunity for cancer constituents to share knowledge and collaborate.

Registration is available online at http://azmyelomanetwork.org/what/2014confreg.html. On-site registration at the conference is 8-9 a.m.

Free continental breakfast and lunch will be provided. Medical professionals may receive 5.75 CME credits.

This year, the conference acknowledges Scottsdale's recent establishment of its "Cure Corridor," which includes many top-tier healthcare providers and researchers assembled along and near Shea Boulevard in the West's Most Western Town.

"Our myeloma conferences have become an important opportunity for patients and families to learn about this rare form of blood cancer and feel less alone," says Barbara Kavanagh, Founder and President of the Arizona Myeloma Network.

The medical faculty for the conference includes: Dr. John Carpten, Translational Genomics Research Institute (TGen); Dr. Robert Kyle, Mayo Clinic, Rochester; Dr. Kenneth Anderson, Dana Farber Cancer Institute, Boston MA; Dr. Frits Van Rhee, UAMS; as well as other outstanding leaders from Banner MD Anderson Cancer Center, Scottsdale Healthcare, Cancer Treatment Centers of America, and local oncology researchers, community physicians, healthcare professionals and the business community.

"The AZMN conference each year provides an outstanding forum for all of those concerned with this debilitating and deadly type of cancer to become better informed about the latest scientific discoveries and the best medical options that might be available," said Dr. Carpten, TGen Deputy Director of Basic Science and Director of TGen's Integrated Cancer Genomics Division.

###

About Arizona Myeloma Network
Myeloma is a complex and often misdiagnosed cancer of bone marrow plasma cells that attacks and destroys the bone. Founded in 2004, the Arizona Myeloma Network (AZMN) is a 501(c)(3) nonprofit charity organization that conducts outreach events and education programs, with special consideration for the underserved African-American, Asian-Pacific, Hispanic American and Native American populations. Volunteers and donations are always welcomed - see www.azmyelomanetwork.org.

Media Contact:
Barbara Kavanagh, AzMN Founder/President
Phone: (623) 388-6837; Fax: (623) 243-6580
[email protected]

*

About TGen
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit:www.tgen.org.

Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]


Search



Media Contact



RSS Feed

Newsletter